185 related articles for article (PubMed ID: 20564079)
21. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
22. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.
Chew HK; Barlow WE; Albain K; Lew D; Gown A; Hayes DF; Gralow J; Hortobagyi GN; Livingston R
Clin Breast Cancer; 2008 Dec; 8(6):511-5. PubMed ID: 19073506
[TBL] [Abstract][Full Text] [Related]
24. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.
Cullinane C; Dorow DS; Kansara M; Conus N; Binns D; Hicks RJ; Ashman LK; McArthur GA; Thomas DM
Cancer Res; 2005 Nov; 65(21):9633-6. PubMed ID: 16266981
[TBL] [Abstract][Full Text] [Related]
25. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
[TBL] [Abstract][Full Text] [Related]
26. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.
McAuliffe JC; Hunt KK; Lazar AJ; Choi H; Qiao W; Thall P; Pollock RE; Benjamin RS; Trent JC
Ann Surg Oncol; 2009 Apr; 16(4):910-9. PubMed ID: 18953611
[TBL] [Abstract][Full Text] [Related]
27. [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].
Raccah E; Merimsky O; Kuten A; Apter S; Catane R
Harefuah; 2007 May; 146(5):329-34, 408. PubMed ID: 17674545
[TBL] [Abstract][Full Text] [Related]
28. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
Yoo C; Ryu MH; Ryoo BY; Beck MY; Kang YK
Invest New Drugs; 2013 Oct; 31(5):1367-74. PubMed ID: 23591629
[TBL] [Abstract][Full Text] [Related]
29. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
Koh Y; Lee HE; Oh DY; Kim JH; Lee SH; Kim SH; Kim DW; Im SA; Kim TY; Heo DS; Kim WH; Bang YJ
Jpn J Clin Oncol; 2012 Nov; 42(11):1020-7. PubMed ID: 22952296
[TBL] [Abstract][Full Text] [Related]
30. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.
Judson IR
J Clin Oncol; 2008 Nov; 26(33):5322-5. PubMed ID: 18955449
[No Abstract] [Full Text] [Related]
31. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
[TBL] [Abstract][Full Text] [Related]
32. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)
J Clin Oncol; 2010 Mar; 28(7):1247-53. PubMed ID: 20124181
[TBL] [Abstract][Full Text] [Related]
33. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
Le Cesne A; Ray-Coquard I; Bui BN; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Cioffi A; Emile JF; Chabaud S; Pérol D; Blay JY;
Lancet Oncol; 2010 Oct; 11(10):942-9. PubMed ID: 20864406
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Demetri GD; Casali PG; Blay JY; von Mehren M; Morgan JA; Bertulli R; Ray-Coquard I; Cassier P; Davey M; Borghaei H; Pink D; Debiec-Rychter M; Cheung W; Bailey SM; Veronese ML; Reichardt A; Fumagalli E; Reichardt P
Clin Cancer Res; 2009 Sep; 15(18):5910-6. PubMed ID: 19723647
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
Ghosal N; Mais K; Shenjere P; Julyan P; Hastings D; Ward T; Ryder WD; Bruce I; Homer J; Slevin NJ
Br J Oral Maxillofac Surg; 2011 Oct; 49(7):510-5. PubMed ID: 21071117
[TBL] [Abstract][Full Text] [Related]
36. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
37. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Spigel DR; Hainsworth JD; Simons L; Meng C; Burris HA; Yardley DA; Grapski R; Schreeder M; Mallidi PV; Greco FA;
J Thorac Oncol; 2007 Sep; 2(9):854-61. PubMed ID: 17805064
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
Matsumoto K; Sawaki A; Mizuno N; Hara K; Hijioka S; Niwa Y; Tajika M; Kawai H; Kondo S; Yamao K
Jpn J Clin Oncol; 2011 Jan; 41(1):57-62. PubMed ID: 20858619
[TBL] [Abstract][Full Text] [Related]
39. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
Blanke CD; Rankin C; Corless C; Eary JF; Mulder K; Okuno SH; George S; Heinrich M
Oncologist; 2015 Dec; 20(12):1353-4. PubMed ID: 26576593
[TBL] [Abstract][Full Text] [Related]
40. 'Time is a GIFT in GIST'--the medical and paramedical perspective of a case with metastatic gastrointestinal stromal tumor.
Sevinc A; Camci C
Chemotherapy; 2009; 55(1):11-4. PubMed ID: 18974643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
